Amphastar Pharmaceuticals, Inc. has disclosed recent stock transactions involving its Chief Financial Officer, William J. Peters. The transactions, reported on November 18, 2026, are notable as they reflect Peters' active engagement with the company's stock, which may signal confidence in Amphastar's future performance.

Background

Amphastar Pharmaceuticals, Inc. operates in the pharmaceutical preparations sector, classified under the SIC code 2834. The company trades on the Nasdaq under the ticker symbol AMPH. As a large accelerated filer, Amphastar is subject to rigorous reporting requirements, ensuring transparency in its financial dealings.

What the Filing Says

The SEC filing details two significant transactions by Peters on November 16, 2026. He acquired 11,000 shares of common stock at a price of $17.99 per share and subsequently sold 11,000 shares at a price of $29.99 per share. Following these transactions, Peters holds a total of 167,076 shares of the company. The filing also notes that the sale was conducted under a Rule 10b5-1 trading plan established on March 10, 2026.

Impact

These transactions may impact various stakeholders, including shareholders and potential investors, as they reflect the financial strategies of Amphastar's leadership. The actions of Peters, who serves as both CFO and Executive Vice President, could influence market perceptions of the company's stability and growth potential.

What's Next

The filing does not say what happens next.